38186-71-9

Upstream product

• 621-59-0 isovanillin 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 

Downstream Products

• 50276-96-5 Ochnaflavone 
• 49619-88-7 penta-O-methylochnaflavon 
• 33554-52-8 3′-hydroxy-5,7,4′-trimethoxyflavone 
• 1386981-16-3 2-methoxy-5-(5,7-dimethoxy-4-oxochroman-2-yl)phenyl phenylcarbamate 
• 26207-74-9 2-(3-hydroxy-4-methoxyphenyl)-5,7-dimethoxychroman-4-one 

Relevant academic research and scientific papers

Synthesis of ochnaflavone and its inhibitory activity on PGE2 production

Ochnaflavone, a naturally occurring biflavonoid composed of two units of apigenin (5,7,4′-trihydroxyflavone) joined via a C-O-C linkage, was first synthesized and evaluated its inhibitory activity on PGE2 production. Total synthesis was accompl

Synthesis and evaluation of novel carbamate-substituted flavanone derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents

This study was designed to synthesize and evaluate flavanone derivatives with phenylcarbamate moiety as potent acetylcholinesterase (AChE) inhibitors and anti-amnestic agents for management of AD. The synthesis of carbamate-substituted flavanone derivativ

Structure - Activity relationship studies of chalcone leading to 3-hydroxy-4,3′,4′,5′-tetramethoxychalcone and its analogues as potent nuclear factor κB inhibitors and their anticancer activities

Chalcone is a privileged structure, demonstrating promising anti-inflammatory and anticancer activities. One potential mechanism is to suppress nuclear factor kappa B (NF-κB) activation. The structures of chalcone-based NF-κB inhibitors vary significantly that there is minimum information about their structure-activity relationships (SAR). This study aims to establish SAR of chalcone-based compounds to NF-κB inhibition, to explore the feasibility of developing simple chalcone-based potent NF-κB inhibitors, and to evaluate their anticancer activities. Three series of chalcones were synthesized in one to three steps with the key step being aldol condensation. These candidates demonstrated a wide range of NF-κB inhibitory activities, some of low micromolar potency, establishing that structural complexity is not required for NF-κB inhibition. Lead compounds also demonstrate potent cytotoxicity against lung cancer cells. Their cytotoxicities correlate moderately well with their NF-κB inhibitory activities, suggesting that suppressing NF-κB activation is likely responsible for at least some of the cytotoxicities. One lead compound effectively inhibits lung tumor growth with no signs of adverse side effects.